Welcome to Macroaxis
Sign in to go to your portfolios
Don't have an account? Create It
  Macroaxis: Personalized Investing   The proven technology to invest wisely
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
  
 
US Market Closed: May 26, 02:47 AM 2012  
VRX HSP ALKS PETS ACUR FLML 
 
 
  NYSE  7,534  18.032  Index Moved Down 



Processing
Collecting data for ELN

Elan quote and profile

    
14.3
  
STOCK
 1.11   Macroaxis: 8.42 Up   8.42%  
 8.58 Year To Date 15.27 
 13.22 Trading Day  14.49 

Diversification Suggestion

Use Elan to enhance returns of your portfolios. The stock experiences very speculative upward sentiment.

1 Month Beta ..........

1.8
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Elan will likely underperform.
Elan Corporation plc Large Beta
ELN United States AMEX
Elan Corporation plc
 
Trade Elan
Current Valuation7.62 B
Shares Outstanding590.8 M
Number of Shares Shorted8.1 M
Revenue1.29 B
 thisGreen ELN ELN agains markets  8.42 % Macroaxis: change 8.42 Moved Up  
 
 United States NASDAQ   0.07 % Macroaxis: 0.07 Moved Down  
 
 United States SP 500   0.22 % Macroaxis: 0.22 Moved Down  
 
 United States NYSE   0.24 % Macroaxis: 0.24 Moved Down  
 

Elan Leadership

G Martin CEO, Executive Director
Kelly Martin CEO and Executive Director
Kathleen Martorano Executive VP of Strategic HR and Member of the Office of the CEO
Robert Ingram Non-Executive Independent Chairman of the Board

Elan Price and Market Media

The median price of Elan for the period between Thu, Apr 26, 2012 and Sat, May 26, 2012 is 13.27 with a coefficient of variation of 3.56. The daily time series for the period is distributed with a sample standard deviation of 0.48, arithmetic mean of 13.36, and mean deviation of 0.39. The Stock received substential amount of media coverage during this period.
Elan         Market
Price Growth (%)
 
Timeline
Biogen_Idec_Q1_net_up_28;_raises_year_viewBiogen Idec Q1 net up 2.8%; raises year view05/01/2012Macroaxis: MarketWatch News
Top_4_Stocks_In_The_Drug_Delivery_Industry_With_The_Highest_Operating_MarginTop 4 Stocks In The Drug Delivery Industry With The Highest Operating Margin05/07/2012Macroaxis: News
Cancer_Tools_Help_Roche_Push_Ahead_With_Alzheimer_and_#39;s_DrugCancer Tools Help Roche Push Ahead With Alzheimer's Drug05/14/2012Macroaxis: News
Revenues_Skyrocket_at_Merged_AlkermesRevenues Skyrocket at Merged Alkermes05/18/2012Macroaxis: News

Elan Summary

Elan Corporation plc [ELN] is traded on American Stock Exchange in USA. It is located in Elan Corporation, plcDublin, and employs 412 people. The company currently falls under 'Mid-Cap' category with total capitalization of 8.45 B. Elan Corporation plc runs under Healthcare sector within Drug Delivery industry. This company has 590.8 M outstanding shares of which 8.1 M shares are currently shorted by investors with about 3.6 days to cover shorted positions.

Elan Liquidity

ELAN CP PLC ADR has about 791.1 M in cash with (1000 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.34.
The company has 615.4 M in debt with debt to equity (D/E) ratio of 0.76 which is OK given its current industry classification. Elan Corporation plc has Current Ratio of 3.25 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Discuss Elan quote and profile

       
       
    
    
Elan
Performance
2
Out Of
100
Over 30
Days
98% of all equities and portfolios perform better than Elan Corporation plc. Compared with the overall equity markets, risk-adjusted returns on investments in Elan Corporation plc are ranked lower than 2 (%) of all global equities and portfolios over the last 30 days.
    
    

Promote Elan

    
Follow Elan with your standard RSS feed, custom widget, or your favorite social app
Add To Reader
 
Add Elan to your reader
 
Get social with Elan
 Get social with Elan 
Share Toggle social options for Elan
    

Add Elan to Your Portfolio

    
Sign in to add this equity to your portfolios   
  
 
    

Elan Research Report

    
    

Elan Executives

Nigel Clerkin CFO and Executive VP

Elan Directors

Dennis Selkoe Non-Executive Independent Director
Kieran McGowan Lead Independent Non-Executive Director
Kyran McLaughlin Non-Executive Independent Director
Gary Kennedy Non-Executive Independent Director
Donal OConnor Non-Executive Independent Director

Elan Management

Allison Hulme Executive VP of Autoimmune, Tysabri and Global Devel. and Head of Autoimmune and Tysabri Franchise
Grainne McAleese Principal Accounting Officer, Group Controller



 

 
Analytics
Investor Landscape
Efficient Frontier
Market Correlation
Risk and Return Analysis
Financial Content
Portfolio Projections
Portfolio Backtesting
Tools
FAQs
Retirement Optimizer
RSS and Mobile Access
Company Directory
Advisor Directory
Insider Directory
Wealth Management
About Us
About Macroaxis
Contact Us
Terms Of Use
Privacy Policy
Custom Reporting
Product Tour
More ROI Custom Reporting